Both tirzepatide and semaglutide are injectable medications used for type 2 diabetes and obesity, but they act slightly differently and have some distinctions:
1. Mechanism of Action
Semaglutide:
-
- A GLP-1 receptor agonist.
-
- Mimics the incretin hormone GLP-1, which increases insulin release, reduces glucagon, slows gastric emptying, and reduces appetite.
Tirzepatide:
-
- A dual GIP/GLP-1 receptor agonist.
-
- Activates both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors.
2. Effectiveness
Weight loss:
-
- Head-to-head trials (e.g., SURPASS-2) found tirzepatide generally produced greater average weight loss than semaglutide at similar doses.
-
- Example: In some studies, tirzepatide led to ~15–20% weight loss vs ~12–15% for high-dose semaglutide.
3. Side Effects
-
- Both can cause: nausea, vomiting, diarrhea, constipation, decreased appetite.
-
- Risk of gallbladder issues, pancreatitis, and rare thyroid tumors (seen in rodents).
4. Dosing
-
- Semaglutide:
-
- Weekly injection (0.25 → 0.5 → 1 mg for diabetes; up to 2.4 mg for obesity).
-
- Semaglutide:
-
- Tirzepatide:
-
- Weekly injection (2.5 → 5 → up to 15 mg).
-
- Tirzepatide:
In summary:
Both are highly effective, but tirzepatide tends to produce greater weight loss and A1C reductions, though GI side effects can be limiting.
Semaglutide = GLP-1 only.
Tirzepatide = GLP-1 + GIP (dual incretin).
| Feature | Tirzepatide | Semaglutide |
|---|---|---|
| Drug class | Dual GIP + GLP-1 receptor agonist | GLP-1 receptor agonist |
| Mechanism | Stimulates both incretin hormones (GIP & GLP-1) → stronger insulin release, reduced glucagon, slower gastric emptying, appetite suppression | Mimics GLP-1 only → insulin release, reduced glucagon, slower gastric emptying, appetite suppression |
| Dosing | Weekly injection (2.5 → 5 → up to 20 mg) |
Weekly injection (0.25 → 0.5 → 1 mg for diabetes, up to 2.4 mg for obesity) |
| Weight loss (trials) | ~15–20% body weight | ~12–15% body weight (with higher dose Wegovy) |
| Side effects (common) | Nausea, vomiting, diarrhea, constipation, decreased appetite | Nausea, vomiting, diarrhea, constipation, decreased appetite |
| Side effects (rare/serious) | Pancreatitis, gallbladder issues, possible thyroid tumors (rodents), GI intolerance | Same risks (pancreatitis, gallbladder, thyroid tumors in rodents) |
Bottom line: Tirzepatide usually offers greater weight loss and blood sugar reduction, while semaglutide has the advantage of being available longer.